Compare Nucor Corporation (NUE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs BIO-TECHNE Corp — how do they compare? Nucor Corporation trades at $256.31 (market cap $58.17B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Nucor Corporation is far larger — about 5.1× BIO-TECHNE Corp's market cap, and Nucor Corporation pays the higher dividend (0.87%). Which is the better fit depends on your goals.
| NUE | TECH | |
|---|---|---|
Market Cap | $58.17B | $11.34B |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $72.48 |
52-Week Low | $131.78 | $43.31 |
Enterprise Value | $62.58B | $11.36B |
Dividend Yield | 0.87% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor Corporation (NUE) trades at $256.40, down 1.79% on the day, with a bullish technical signal supported by moving averages and strong institutional interest. The company shows improving fundamentals with recent earnings beats (Q1 and Q2 2026) and projected revenue growth to $36.1B in 2026. Analyst consensus remains positive with a $277.57 price target, though recent trade tensions and cyclical steel industry challenges present headwinds.
NUE offers value with reasonable valuation multiples (P/E 20.46, P/S 1.63) and strong profitability metrics (ROE 13.52%). Key risks include exposure to steel price volatility and macroeconomic sensitivity, but infrastructure demand and tariff protections provide tailwinds. Institutional accumulation and dividend stability support the investment case for long-term investors.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
